tiprankstipranks
Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results
Company Announcements

Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results

Don't Miss our Black Friday Offers:

Imunon (IMNN) has provided an announcement.

Imunon, Inc. has revealed encouraging results from its Phase 2 OVATION 2 trial, which tested IMNN-001 alongside standard chemotherapy treatments for advanced ovarian cancer. The data indicates that the treatment could potentially extend the median time to event and improve overall survival rates, although statistical significance was not reached. Investors and interested parties are invited to a conference call and can access more information via a webcast or the investor presentation on the company’s website.

For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImunon, Inc. Reports Q3 2024 Earnings and Progress
TheFlyImunon presents data from Phase 2 OVATION 2 clinical trial
TheFlyImunon reports Q3 EPS (34c), consensus (40c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App